HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3161-3168

  Kim, Mi Joung ^a   Kim, Dong Eun ^a   Jeong, In Gab ^a   Choi, Jene ^a   Jang, Sejin ^a   Lee, Je Hwan ^a   Ro, Seonggu ^a,b   Hwang, Jung Jin ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

Apoptosis; Histone deacetylase inhibitor; Renal cell carcinoma; Sorafenib

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BELINOSTAT; CASPASE 3; CASPASE 8; CASPASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MCL 1; SORAFENIB; TUBULIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; IC 50; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KIDNEY NEOPLASMS; PYRIDINES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84865683588     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Basso M, Cassano A and Barone C: A survey of therapy for advanced renal cell carcinoma. Urol Oncol 28: 121-133, 2010.
2. Fisher R, Pickering L and Larkin J: New targeted therapies for renal cell carcinoma. Expert Opin Inv Drug 20: 933-945, 2011.
3. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M and de Bruine AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138, 2010.
4. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006.
5. Iyer R, Fetterly G, Lugade A and Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11: 1943-1955, 2010.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
7. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
8. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M and Kristiansen G: Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. Bmc Cancer 8: 381-391, 2008.
9. Bots M and Johnstone RW: Rational combinations using HDAC Inhibitors. Clin Cancer Res 15: 3970-3977, 2009.
10. Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165, 2006.
11. Ma X, Ezzeldin HH and Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934, 2009.
12. Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG and Kim CS: Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone-refractory prostate cancer cells. J Urol 184: 2557-2564, 2010.
13. Brugarolas J: Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 356: 185-187, 2007.
14. Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol 33: 637-646, 2008.
15. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 99: 292-298, 2002.
16. Xiao JJ, Foraker AB, Swaan PW, Liu SJ, Huang Y, Dai ZY, Chen JY, Sadee W, Byrd J, Marcucci G and Chan KK: Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein. J Pharmacol Exp Ther 313: 268-276, 2005.
17. Dasmahapatra G, Nitin Y, Dai Y, Dent P and Grant S: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve MCL-1 and p21(CIP1) down-regulation. Clin Cancer Res 13: 4280-4290, 2007.
18. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S and Dent P: Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14: 5385-5399, 2008.
19. Baradari V, Hopfner M, Huether A, Schuppan D and Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong anti proliferative action in human cholangiocarcinoma cells. World J Gastroenterol 13: 4458-4466, 2007.
20. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S and Wolff JE: Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 32: 511-514, 2010.
21. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H and Kim KW: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300: 241-246, 2003.
22. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, Lv YM, Yang CX and Liu YW: Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 25: 593-599, 2006.
23. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA and Heymach JV: Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29: 2938-2949, 2010.